**Proteins** 



# A-317567

Cat. No.: HY-122135 CAS No.: 371217-32-2 Molecular Formula:  $C_{27}^{}H_{31}^{}N_{3}^{}$ Molecular Weight: 397.56

Target: Sodium Channel

Pathway: Membrane Transporter/Ion Channel

Storage: 4°C, protect from light

\* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 50 mg/mL (125.77 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.5153 mL	12.5767 mL	25.1534 mL
	5 mM	0.5031 mL	2.5153 mL	5.0307 mL
	10 mM	0.2515 mL	1.2577 mL	2.5153 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.23 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.23 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	A-317567 is a potent acid-sensing ion channel 3 (ASIC-3) inhibitor with an IC $_{50}$ of 1.025 $\mu$ M. A-317567 has antidepressant and antinociception effects $^{[1][2]}$ .
IC <sub>50</sub> & Target	IC50: 1.025 μM (Acid-sensing ion channel 3 (ASIC-3)) <sup>[1]</sup>
In Vitro	In acutely dissociated adult rat dorsal root ganglion (DRG) neurons, A-317567 produces concentration-dependent inhibition of all pH 4.5-evoked ASIC currents with an IC $_{50}$ ranging between 2 and 30 $\mu$ M. A-317567 equipotently blocks the sustained phase of ASIC3-like current, a biphasic current akin to cloned ASIC3, which is predominant in DRG $^{[2]}$ . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	A-317567 (1-100 $\mu$ mol/kg; i.p; once) is fully analgesic effects in the CFA model (ED <sub>50</sub> of 17 $\mu$ mol/kg). There is no significant

	ne withdrawal latency of the contralateral paw under these conditions <sup>[2]</sup> .  Ently confirmed the accuracy of these methods. They are for reference only.	
Animal Model:	Adult male Sprague-Dawley rats (230-350 g) injected with Complete Freund's Adjuvant-(CFA-) induced thermal hyperalgesia <sup>[2]</sup> .	
Dosage:	1-100 μmol/kg	
Administration:	i.p; once	
Result:	Showed dose-dependent analgesic effects.	

#### **REFERENCES**

[1]. Kuduk SD, et al. Synthesis, structure-activity relationship, and pharmacological profile of analogs of the ASIC-3 inhibitor A-317567. ACS Chem Neurosci. 2010 Jan 20;1(1):19-24.

[2]. Dubé GR, et al. Electrophysiological and in vivo characterization of A-317567, a novel blocker of acid sensing ion channels. Pain. 2005 Sep;117(1-2):88-96.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA